Interestingly, a therapeutic approach based on tumour vaccine therapy showed that stimulating autologous T cells from MM patients with DKK1 peptides as the immunogen was able to specifically target myeloma cells without affecting normal blood cells [84]. The gene discussed is DKK1; the disease is neoplasm.